FLT3 and acute myeloid leukemia: Midostaurin, a first-generation FLT3-inhibitor, added to induction and consolidation chemotherapy and as single agent for remission maintenance, significantly improved the overall survival and event-free survival of patients with FLT3-mutated AML in the RATIFY trial [3].